SG11201704200SA - Indirect homogeneous mobility shift assays for the detection of biologics in patient samples - Google Patents
Indirect homogeneous mobility shift assays for the detection of biologics in patient samplesInfo
- Publication number
- SG11201704200SA SG11201704200SA SG11201704200SA SG11201704200SA SG11201704200SA SG 11201704200S A SG11201704200S A SG 11201704200SA SG 11201704200S A SG11201704200S A SG 11201704200SA SG 11201704200S A SG11201704200S A SG 11201704200SA SG 11201704200S A SG11201704200S A SG 11201704200SA
- Authority
- SG
- Singapore
- Prior art keywords
- biologics
- detection
- patient samples
- mobility shift
- shift assays
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5434—IL-12
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088465P | 2014-12-05 | 2014-12-05 | |
US201562113317P | 2015-02-06 | 2015-02-06 | |
US201562158791P | 2015-05-08 | 2015-05-08 | |
PCT/IB2015/059381 WO2016088104A2 (en) | 2014-12-05 | 2015-12-04 | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704200SA true SG11201704200SA (en) | 2017-06-29 |
Family
ID=55025290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704200SA SG11201704200SA (en) | 2014-12-05 | 2015-12-04 | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
Country Status (15)
Country | Link |
---|---|
US (3) | US10422807B2 (zh) |
EP (2) | EP3536705A1 (zh) |
JP (1) | JP2018500553A (zh) |
KR (1) | KR20170091717A (zh) |
CN (1) | CN107250798A (zh) |
AU (1) | AU2015356613A1 (zh) |
BR (1) | BR112017011545A2 (zh) |
CA (1) | CA2969609C (zh) |
ES (1) | ES2735085T3 (zh) |
HK (1) | HK1244880B (zh) |
IL (1) | IL252396A0 (zh) |
MX (1) | MX2017007232A (zh) |
RU (1) | RU2017122720A (zh) |
SG (1) | SG11201704200SA (zh) |
WO (1) | WO2016088104A2 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012009855A2 (pt) | 2009-10-26 | 2018-06-26 | Prometheus Laboratoires Inc | métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit |
SG10201605516YA (en) | 2011-07-06 | 2016-08-30 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
CA2969609C (en) | 2014-12-05 | 2023-02-28 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
CN114624343B (zh) * | 2020-12-10 | 2023-01-24 | 中国科学院大连化学物理研究所 | 一种用于血清中45种炎症及免疫代谢物相对定量的方法 |
AU2022359021A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
CA3234496A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3107755A1 (de) | 1981-02-28 | 1982-09-16 | Degussa Ag, 6000 Frankfurt | Katalysatoren fuer die herstellung von 3-cyanpyridin |
US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
US4459359A (en) | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
EP0440044A1 (en) | 1990-01-31 | 1991-08-07 | Abbott Laboratories | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing |
US5094740A (en) | 1990-02-16 | 1992-03-10 | Glycomed, Inc. | Two-dimensional electrophoretic separation of carbohydrates |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
JPH04303867A (ja) | 1991-03-30 | 1992-10-27 | Toshiba Corp | 画像形成装置 |
US5582998A (en) | 1991-06-19 | 1996-12-10 | Boehringer Ingelheim International Gmbh | Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor |
JPH0566222A (ja) | 1991-09-09 | 1993-03-19 | Tosoh Corp | 物質の分析方法 |
AU678787B2 (en) * | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
ES2150970T3 (es) | 1993-09-07 | 2000-12-16 | Wako Pure Chem Ind Ltd | Procedimiento y reactivo para la medida de la actividad del complemento. |
JPH07110331A (ja) | 1993-09-07 | 1995-04-25 | Wako Pure Chem Ind Ltd | ヒト補体価測定方法及びヒト補体価測定用試薬組成物 |
JPH07140144A (ja) | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的IgE抗体の測定方法および抗原抗体複合体の測定方法 |
DK0800578T3 (da) | 1994-12-28 | 2003-08-11 | Univ Kentucky | Rekombinant monoklonalt anti-idiotype antistof 3H1 |
US6903183B1 (en) | 1996-06-07 | 2005-06-07 | Texas Tech University Health Services Center | Compositions and methods for regulation of steroidogenesis |
JP3718435B2 (ja) | 1996-08-12 | 2005-11-24 | 積水化学工業株式会社 | 細胞機能測定用容器及び細胞機能測定方法 |
CA2234165C (en) | 1996-08-12 | 2004-10-26 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Containers and kits for the determination of cell functions, and method for the determination thereof |
US6391622B1 (en) | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
DE19858777B4 (de) | 1998-12-18 | 2006-07-27 | Delta Biotechnology Ltd. | Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
EP1238077A1 (en) | 1999-12-16 | 2002-09-11 | Amgen Inc., | Tnfr/opg-like molecules and uses thereof |
US7323552B2 (en) * | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
WO2002081518A2 (en) * | 2001-02-21 | 2002-10-17 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
EP1637601A3 (en) * | 2001-02-21 | 2006-03-29 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
DE60237194D1 (de) | 2001-03-02 | 2010-09-16 | Activx Biosciences Inc | Plattform für protein-profiling |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2003019136A2 (en) * | 2001-08-06 | 2003-03-06 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
WO2003016909A1 (en) | 2001-08-16 | 2003-02-27 | Ludwig Institute For Cancer Research | Method for determining protein component in a biological sample |
CA2466592A1 (en) | 2001-11-12 | 2003-05-22 | Koen Hellendoorn | Modified anti-tnf alpha antibody |
WO2003049117A2 (en) | 2001-12-05 | 2003-06-12 | Cangene Corporation | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
CN1700930A (zh) | 2002-08-01 | 2005-11-23 | 惠氏公司 | 炎症和细胞凋亡相关的方法与试剂 |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
US7648825B2 (en) | 2003-06-20 | 2010-01-19 | University Of Florida Research Foundation, Inc. | Biomarkers for differentiating between type 1 and type 2 diabetes |
CA2533796A1 (en) | 2003-08-01 | 2005-02-10 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスy抗イディオタイプ抗体およびその使用 |
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
WO2005072340A2 (en) * | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
US20090275496A1 (en) | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
US20060003384A1 (en) | 2004-06-30 | 2006-01-05 | Wagner Carrie L | Detection of measurement of antibodies to antigenic proteins in biological tissues or samples |
US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
BRPI0613259A2 (pt) | 2005-05-20 | 2010-12-28 | Genentech Inc | método de tratamento de amostra biológica e kit de diagnóstico |
SG164379A1 (en) | 2005-07-21 | 2010-09-29 | Genmab As | Potency assays for antibody drug substance binding to an fc receptor |
US20090162374A1 (en) | 2005-09-14 | 2009-06-25 | Geraghty Daniel E | Specific removal of activated immune cells |
US7542502B2 (en) | 2005-09-27 | 2009-06-02 | Cymer, Inc. | Thermal-expansion tolerant, preionizer electrode for a gas discharge laser |
CA2626859A1 (en) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
JP2007147367A (ja) | 2005-11-25 | 2007-06-14 | Sekisui Chem Co Ltd | サイトカイン産生能の測定方法 |
DE102005057920A1 (de) | 2005-12-02 | 2007-06-28 | Strohner, Pavel, Dr. | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben |
US20100130367A1 (en) | 2006-07-11 | 2010-05-27 | Drexel University | Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles |
US7993833B2 (en) * | 2006-09-11 | 2011-08-09 | Celera Corporation | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
US9250243B2 (en) | 2006-09-21 | 2016-02-02 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
US20080286774A1 (en) * | 2007-05-16 | 2008-11-20 | The Regents Of The University Of California | Real-time individualized therapy evaluation |
US20090035216A1 (en) | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
WO2009042114A2 (en) | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
EP2240769A1 (en) | 2008-01-15 | 2010-10-20 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
CN102016552A (zh) | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | 用于分子的高灵敏性检测的方法和组合物 |
US8877893B2 (en) * | 2008-12-29 | 2014-11-04 | Children's Medical Center Corporation | Stabilized low affinity conformation of integrins for drug discovery |
BR112012009855A2 (pt) | 2009-10-26 | 2018-06-26 | Prometheus Laboratoires Inc | métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit |
DK2547359T3 (en) * | 2010-03-15 | 2016-06-06 | The Board Of Trustees Of The Univ Of Illionis | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS |
JP5066222B2 (ja) | 2010-05-31 | 2012-11-07 | 三菱電機株式会社 | ネットワーク解析支援装置、ネットワーク解析支援方法及びプログラム |
EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
EP2676137B1 (en) | 2011-02-17 | 2014-12-31 | Nestec S.A. | Assays for detecting autoantibodies to anti-tnf drugs |
RS56429B1 (sr) | 2011-05-02 | 2018-01-31 | Millennium Pharm Inc | Formulacija za anti- 4 7 antitelo |
AU2012253422B2 (en) | 2011-05-10 | 2015-08-13 | Société des Produits Nestlé S.A. | Methods of disease activity profiling for personalized therapy management |
EP2723361B1 (en) * | 2011-06-22 | 2019-10-30 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
CA2840577A1 (en) * | 2011-06-30 | 2013-01-03 | Immuno-Biological Laboratories Co., Ltd. | Soluble integrin .alpha.4 mutant |
SG10201605516YA (en) | 2011-07-06 | 2016-08-30 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
US20130266963A1 (en) | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
WO2013126595A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye And Ear Infirmary | Methods for treating corneal and conjunctival inflammation and inflammatory disorders |
US20130295685A1 (en) | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
US20140051184A1 (en) * | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
BR112015012482A2 (pt) | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
TWI736515B (zh) | 2013-11-13 | 2021-08-21 | 美商輝瑞大藥廠 | 類腫瘤壞死因子之配體1a之專一性抗體及其組合物及用途 |
CA2969609C (en) * | 2014-12-05 | 2023-02-28 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
KR102423893B1 (ko) | 2015-03-31 | 2022-07-21 | 삼성디스플레이 주식회사 | 플렉서블 표시 장치 |
MX2019006864A (es) | 2016-12-14 | 2019-10-15 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). |
-
2015
- 2015-12-04 CA CA2969609A patent/CA2969609C/en active Active
- 2015-12-04 RU RU2017122720A patent/RU2017122720A/ru not_active Application Discontinuation
- 2015-12-04 EP EP19163825.3A patent/EP3536705A1/en not_active Withdrawn
- 2015-12-04 ES ES15816881T patent/ES2735085T3/es active Active
- 2015-12-04 SG SG11201704200SA patent/SG11201704200SA/en unknown
- 2015-12-04 BR BR112017011545A patent/BR112017011545A2/pt not_active Application Discontinuation
- 2015-12-04 MX MX2017007232A patent/MX2017007232A/es unknown
- 2015-12-04 WO PCT/IB2015/059381 patent/WO2016088104A2/en active Application Filing
- 2015-12-04 KR KR1020177018320A patent/KR20170091717A/ko unknown
- 2015-12-04 CN CN201580075470.7A patent/CN107250798A/zh active Pending
- 2015-12-04 JP JP2017529694A patent/JP2018500553A/ja not_active Ceased
- 2015-12-04 EP EP15816881.5A patent/EP3227683B1/en not_active Not-in-force
- 2015-12-04 AU AU2015356613A patent/AU2015356613A1/en not_active Abandoned
-
2017
- 2017-05-21 IL IL252396A patent/IL252396A0/en unknown
- 2017-05-23 US US15/603,137 patent/US10422807B2/en active Active
-
2018
- 2018-03-29 HK HK18104343.6A patent/HK1244880B/zh not_active IP Right Cessation
-
2019
- 2019-08-09 US US16/536,777 patent/US11846642B2/en active Active
-
2023
- 2023-10-12 US US18/485,566 patent/US20240183867A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20170091717A (ko) | 2017-08-09 |
HK1244880B (zh) | 2020-06-05 |
JP2018500553A (ja) | 2018-01-11 |
CN107250798A (zh) | 2017-10-13 |
US20200088749A1 (en) | 2020-03-19 |
CA2969609C (en) | 2023-02-28 |
EP3536705A1 (en) | 2019-09-11 |
CA2969609A1 (en) | 2016-06-09 |
RU2017122720A (ru) | 2019-01-10 |
MX2017007232A (es) | 2017-10-16 |
ES2735085T3 (es) | 2019-12-16 |
BR112017011545A2 (pt) | 2018-03-13 |
US10422807B2 (en) | 2019-09-24 |
US20240183867A1 (en) | 2024-06-06 |
AU2015356613A1 (en) | 2017-06-15 |
WO2016088104A2 (en) | 2016-06-09 |
WO2016088104A3 (en) | 2016-08-18 |
EP3227683B1 (en) | 2019-04-24 |
US20170328923A1 (en) | 2017-11-16 |
US11846642B2 (en) | 2023-12-19 |
IL252396A0 (en) | 2017-07-31 |
EP3227683A2 (en) | 2017-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265396A (en) | Methods and compositions for detecting analytes | |
HK1244465A1 (zh) | 微流體裝置中測定陽性的區域的自動檢測 | |
EP3139841A4 (en) | Specimen collection device | |
SG10201913420XA (en) | Urinalysis device and dry reagent for quantitative urinalysis | |
IL252396A0 (en) | Indirect homogeneous mobility detection test for the detection of biological samples of a patient | |
PT3272874T (pt) | Composição de reagente para biossensor e biossensor tendo a mesma | |
GB201402550D0 (en) | Assay device | |
AU359757S (en) | Biological indicator vial | |
GB2550006B (en) | Establishing presence by identifying audio sample and position | |
DK3123177T3 (da) | Prøveselektor | |
GB201413157D0 (en) | Sample analysing device | |
SG11201507949YA (en) | Biological sample processing | |
HUE047156T2 (hu) | Peptidek, eszközök és eljárások Anaplasma-ellenanyagok kimutatására | |
HK1245885A1 (zh) | 用於定量血液樣品的方法和裝置 | |
EP3099739A4 (en) | Paramagnetic supports for use as assay reagents | |
IL246642A0 (en) | Materials and methods for quantifying pld-1 protein levels | |
GB2523639B (en) | Modified measuring cuvette | |
DK3144681T3 (da) | Prøveanalyseindretning | |
GB201412156D0 (en) | Analyte concentration measurement | |
GB201513460D0 (en) | Imagable specimen sample | |
SG11201608473RA (en) | Devices and kits for measuring biological results | |
EP3220129A4 (en) | Analyte measurement device | |
EP3144679A4 (en) | Sample analysis device | |
GB201405856D0 (en) | Functional antibody assay | |
IL254982B (en) | Method and system for taking samples for biopsy |